Research information only, not medical advice. 5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT) — not a peptide, despite often being grouped with them. It is investigational and has not been approved by the FDA for any use; it is sold only for laboratory research. As of 2026 there are no published human clinical trials, and human safety data are absent.
5-Amino-1MQ at a glance
The evidence for 5-Amino-1MQ is preclinical. In rodent studies, inhibiting NNMT with 5-Amino-1MQ or related small molecules reduced body-weight gain and adipose tissue without reducing food intake or lean body mass, an effect attributed to preserving cellular NAD+ and SAM. As of 2026, no human clinical trial of 5-Amino-1MQ has been published and none appears completed in trial registries; its effects and safety in people are untested.
See how we grade evidence for the methodology behind this page.
Evidence profile
3 studies- Animal 1 · 33%
- In-vitro 2 · 67%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
Indexed research
Sorted by evidence level, strongest first.
- Animal 2022Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice
- In-vitro 2024NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer
- In-vitro 2021Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells
Frequently asked questions
- Is 5-Amino-1MQ approved for human use?
- 5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT) — not a peptide, despite often being grouped with them. It is investigational and has not been approved by the FDA for any use; it is sold only for laboratory research. As of 2026 there are no published human clinical trials, and human safety data are absent.
- What does the research on 5-Amino-1MQ show?
- The evidence for 5-Amino-1MQ is preclinical. In rodent studies, inhibiting NNMT with 5-Amino-1MQ or related small molecules reduced body-weight gain and adipose tissue without reducing food intake or lean body mass, an effect attributed to preserving cellular NAD+ and SAM. As of 2026, no human clinical trial of 5-Amino-1MQ has been published and none appears completed in trial registries; its effects and safety in people are untested.